Emerging Infectious Diseases (Dec 2024)

Cost-effectiveness Analysis of Japanese Encephalitis Vaccination for Children <15 Years of Age, Bangladesh

  • An Nguyen,
  • Rebeca Sultana,
  • Elisabeth Vodicka,
  • Zareen Tasnim,
  • Kamran Mehedi,
  • Md. Monjurul Islam,
  • S.M. Abdullah Al Murad,
  • Md. Redowan Ullah,
  • Sharmin Sultana,
  • Tahmina Shirin,
  • Clint Pecenka

DOI
https://doi.org/10.3201/eid3012.231657
Journal volume & issue
Vol. 30, no. 12
pp. 2593 – 2603

Abstract

Read online

Japanese encephalitis (JE) is preventable using the affordable, effective, and safe live attenuated SA 14-14-2 JE vaccine (CD-JEV). We used a Markov model to evaluate the cost-effectiveness of 1 dose of CD-JEV compared with no vaccination in 3 vaccination strategies in Bangladesh: subnational campaign and routine immunization, subnational campaign and national routine immunization, and national routine immunization alone. For input parameters, we gathered information from a cost-of-illness study, medical literature, government documents, and expert opinions. The base-case analysis estimated that a subnational campaign for children <15 years of age and routine immunization over 20 birth cohorts in Rajshahi, Rangpur, and Chattogram yielded (in 2021 US dollars) a cost of $82.2 million, $981/disability-adjusted life years averted, $9,964/case averted, and $49,819/death averted (societal perspective). We projected CD-JEV vaccination would be cost-effective across cost perspectives and vaccination strategies in Bangladesh, yielding an incremental cost-effectiveness ratio of approximately one third of per capita national gross domestic product.

Keywords